{
  "results": [
    {
      "title": "Childhood Liver Cancer Treatment (PDQ®)–Patient Version - National Cancer Institute",
      "url": "https://www.cancer.gov/types/liver/patient/child-liver-treatment-pdq",
      "contentType": "pdqCancerInfoSummary",
      "description": "Treatment for pediatric liver cancer depends on many factors, including the type of cancer and whether it has spread. When possible, liver cancer is removed by surgery. Learn about the types of treatment options for childhood liver cancers."
    },
    {
      "title": "Liver (Hepatocellular) Cancer Prevention (PDQ®)–Patient Version - National Cancer Institute",
      "url": "https://www.cancer.gov/types/liver/patient/liver-prevention-pdq",
      "contentType": "pdqCancerInfoSummary",
      "description": "Liver cancer risk factors include hepatitis B and C, cirrhosis, and aflatoxin (poison from certain foods). Learn about these and other risk factors for liver cancer and how to prevent liver cancer in this expert-reviewed and evidence-based summary."
    },
    {
      "title": "Liver (Hepatocellular) Cancer Screening (PDQ®)–Patient Version - National Cancer Institute",
      "url": "https://www.cancer.gov/types/liver/patient/liver-screening-pdq",
      "contentType": "pdqCancerInfoSummary",
      "description": "Liver (hepatocellular) cancer screening is not currently recommended as a routine part of cancer screening. Not all screening tests are helpful, and many have risks. Learn more about liver cancer and the tests used to detect it in this expert-reviewed summary."
    },
    {
      "title": "Advances in Liver Cancer Research - National Cancer Institute",
      "url": "https://www.cancer.gov/types/liver/research",
      "contentType": "cgvArticle",
      "description": "An overview of recent research results and progress related to the prevention, early detection, and treatment of liver cancer, including research related to biomarkers, cirrhosis, and hepatitis infections. Selected NCI-supported programs that address liver cancer are also described."
    },
    {
      "title": "Liver and Bile Duct Cancer—Patient Version - National Cancer Institute",
      "url": "https://www.cancer.gov/types/liver",
      "contentType": "cgvCancerTypeHome",
      "description": "Liver cancer includes hepatocellular carcinoma and bile duct cancer (cholangiocarcinoma). Risk factors for HCC include chronic infection with hepatitis B or C and cirrhosis of the liver. Start here to find information on liver and bile duct cancer treatment, causes and prevention, screening, research, and statistics."
    },
    {
      "title": "Liver and Bile Duct Cancer—Health Professional Version - National Cancer Institute",
      "url": "https://www.cancer.gov/types/liver/hp",
      "contentType": "cgvCancerTypeHome",
      "description": "Liver cancer includes two major types: hepatocellular carcinoma (HCC) and intrahepatic bile duct cancer, also known as cholangiocarcinoma. Find evidence-based information on liver and bile duct cancer treatment, causes and prevention, screening, research, genomics and statistics."
    },
    {
      "title": "Liver Cancer Clinical Trials - National Cancer Institute",
      "url": "https://www.cancer.gov/about-cancer/treatment/clinical-trials/disease/liver-cancer",
      "contentType": "nciAppModulePage",
      "description": "NCI supports clinical trials studying new and more effective ways to detect and treat cancer. Find clinical trials for liver cancer."
    },
    {
      "title": "Drugs Approved for Liver Cancer - National Cancer Institute",
      "url": "https://www.cancer.gov/about-cancer/treatment/drugs/liver",
      "contentType": "cgvArticle",
      "description": "This page lists cancer drugs approved by the Food and Drug Administration (FDA) for liver cancer. The list includes generic names and brand names. The drug names link to NCI’s Cancer Drug Information summaries."
    },
    {
      "title": "Nivolumab Approved by FDA for Liver Cancer - National Cancer Institute",
      "url": "https://www.cancer.gov/news-events/cancer-currents-blog/2017/opdivo-fda-liver",
      "contentType": "cgvBlogPost",
      "description": "The immunotherapy nivolumab (Opdivo®) has been approved by FDA for patients with advanced liver cancer who have previously been treated with sorafenib (Nexavar®)."
    },
    {
      "title": "FDA Approves Regorafenib for Liver Cancer - National Cancer Institute",
      "url": "https://www.cancer.gov/news-events/cancer-currents-blog/2017/fda-regorafenib-liver",
      "contentType": "cgvBlogPost",
      "description": "An NCI Cancer Currents blog on FDA’s approval of regorafenib (Stivarga®), the first drug approved for liver cancer in nearly a decade."
    }
  ],
  "totalResults": 4157
}
